



PATENT

In re Application of: Jeppesen et al.

Serial No.: 09/940,963 ✓

Group Art Unit: To be assigned

Filed: August 28, 2001

Examiner: To be assigned

For: Heterocyclic Compounds, their Preparation and Use

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to File Corrected Application Papers dated September 18, 2001 (a copy thereof is attached hereto), Applicants submit a Preliminary Amendment incorporating the requested abstract for the above-captioned application.


Additionally, the Cross Reference to Related Application section has been added to the specification.

Please charge any debits or overpayments to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Respectfully submitted,

Date: November 16, 2001

Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



PATENT TRADEMARK OFFICE



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/940,963	08/28/2001	Lone Jeppesen	4759 224-US

CONFIRMATION NO. 7017

FORMALITIES LETTER



OC00000006567653

Reza Green, Esq.
Novo Nordisk of North America, Inc.
Suite 6400
405 Lexington Avenue
New York, NY 10174-6401

Date Mailed: 09/18/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

FOEET "E9604650